Venus Remedies share news, announcements and annual reports
NSE: VENUSREMBSE: 526953Pharmaceuticals & BiotechnologySmall Cap
Venus Remedies Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1995 on BSE, Dec 2006 on NSE
Last close ₹1,238.60down ₹50.70 (3.93%)BSE ₹1,231.75
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,289.30.
30 Oct: open ₹1,290.00, high ₹1,319.00, low ₹1,225.10
52-week range of traded prices to 30 Oct 2026
₹432.10Low, 31 Oct 2025₹2,044.30High, 29 Jun 2026
- Under NSE's long-term additional surveillance, stage IV, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,656 Cr1,337th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 13.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.35
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.81%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 48,127
Venus Remedies board meetings
168 filed, newest first. Page 4 of 4.
Oct 2009
31 Oct · Board meeting
Board of Directors at its meeting held on October 31, 2009 have unanimously elected Mr. Pawan Chaudhary the Managing Director as the Chairman of the Board of Directors.21 Oct · Board meeting
To consider interalia Unaudited Financial Results (Provisional) for the quarter ended September 30, 2009.
Aug 2009
11 Aug · Board meeting
To inter alia consider and approve : (1) Annual Accounts of the Company for the year ended March 31, 2009, (2) Recommendation of dividend for the year 2008-2009, (3) Fix the Date of Annual General Meeting, (4) Any other business with the permission of the Chair.
Jul 2009
25 Jul · Board meeting
To consider interalia Unaudited Financial Results (Provisional) for the quarter ended June 30, 2009.
Apr 2009
21 Apr · Board meeting
To consider interalia Unaudited Financial Results (Provisional) for the quarter ended March 31, 2009 and to consider allotment of shares under Employees Stock Options Scheme.
Jan 2009
19 Jan · Board meeting
Meeting on 31 Jan 2009: “Unaudited Financial Results for the qtr ended Dec 31, 2008”
Oct 2008
14 Oct · Board meeting
Meeting on 30 Oct 2008: “Unaudited financial results for qtr ended September 30, 2008”
Jul 2008
21 Jul · Board meeting
To inter alia consider and approve: 1) Unaudited Financial Results (Provisional) for the quarter ended June 30, 2008, 2) Annual Accounts of the Company for the year ended March 31, 2008, 3) Recommendation of dividend for the year 2007-2008, 4) Fix the Date of Annual General Meeting, 5) Enhancement in remuneration of working directors, 6) Change of Registered Office within the same city, 7) Any other business with the permission of the Chair.
Apr 2008
16 Apr · Board meeting
Meeting on 29 Apr 2008: “Unaudited Financial Results for the qtr ended March 31, 2008”
Jan 2008
15 Jan · Board meeting
To consider interalia Unaudited Financial Results (Provisional) for the quarter ended December 31, 2007 and to consider allotment of shares under Employees Stock Options Scheme (ESOP).
Oct 2007
15 Oct · Board meeting
Meeting on 22 Oct 2007: “Unaudited Financial Results for the Qtr ended Sept 30, 2007”
Aug 2007
13 Aug · Board meeting
To inter alia consider & approve Annual Accounts of the Company for the year ended March 31, 2007 & recommendation of Dividend for the same period.
Jul 2007
16 Jul · Board meeting
Meeting on 23 Jul 2007: “Unaudited financial results for quarter ended June 30, 2007”
Apr 2007
25 Apr · Board meeting
Board of Directors at its meeting held today on April 25, 2007 have approved allotment of 23,528 equity shares under Employees Stock Options Scheme pursuant to exercise of options granted. Further, Mr. Ashutosh Jain, Vice President, has been appointed as an Additional Director in whole time employment as Executive Director in charge of HR, Administration, regulatory Affairs, Legal and Projects".16 Apr · Board meeting
To consider interalia Unaudited financial Results (Provisional) for the quarter ended 31/3/2007 and to consider allotment of shares under Employees Stock Options Scheme (ESOS).
Feb 2007
7 Feb · Board meeting
Subject to the approval of shareholders in the Extra ordinary General Meeting to be held on March 5, 2007, the Board of Directors at its meeting held today on February 6, 2007 approved enhancing the FII investment limit in the company from 24% to 49% of the paid up equity capital of company.
Jan 2007
29 Jan · Board meeting
To consider inter alia enhancing the limit of FII's and NRI's in paid up equity capital of the Company and to consider holding of Extra Ordinary General Meeting for the approval of the Shareholders.4 Jan · Board meeting
Meeting on 15 Jan 2007: “Unaudited Financial Results for the quarter ended Dec 31, 06”